Phenex Pharmaceuticals Ag

Orsobio, Inc.

Phenix Pharmaceuticals Ag

Ulrich Deuschle

Claus Kremoser

John S Kiely

Christian Gege

Olaf Kinzel

Ronnie C Hanecak

Elena Dneprovskaia

Kerstin Otte

Normand Hébert

Ingo Kober

Manfred Kögl

Harald Kranz

Matthew Lee

Carlton Sage

Manish Sud

Eva Hambruch

Ulrike Bauer

Manfred Birkel

Zach Cheruvallath

Tim Gahman

Kristina Giegrich

Christoph Steeneck

Thomas Hoffmann

Michael Albers

Ulrich Abel

Andreas Schulz

The present invention relates to bicyclic compounds (e.g. indoles) containing a sulfonyl moiety, which bind to the liver X receptor (LXRa and/or LXKJ3) and act preferably as inverse agonists of LXR.

LXR modulators with bicyclic core moiety

The present invention relates to bicyclic compounds (e.g. indoles) containing a sulfonyl moiety, which bind to the liver X receptor (LXRα and/or LXKβ) and act preferably as inverse agonists of LXR.

The present invention relates to bicyclic compounds (e.g. indoles) containing a sulfonyl moiety, which bind to the liver X receptor (LXR&#x3b1; and/or LXK&#x3b2;) and act preferably as inverse agonists of LXR. 

The present invention relates to compounds which can act as aryl hydrocarbon receptor (AhR) modulators and, in particular, as AhR antagonists. The invention further relates to the use of the compounds for the treatment and/or prophylaxis of diseases and/or conditions through binding of said aryl hydrocarbon receptor by said compounds. 

Aryl hydrocarbon receptor (AhR) modulator compounds

Aryl hydrocarbon receptor (AHR) modulator compounds

The present invention relates to compounds which bind to the NR1H4 receptor (FXR) and act as agonists or partial agonists of the NR1H4 receptor (FXR). The invention further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds, and to a process for the synthesis of said compounds.

Heterocyclic FXR binding compounds

The invention provides compounds according to the general formula () which bind to the NRHreceptor and act as agonists, antagonists or mixed agonists/antagonists of the NRHreceptor. The invention further provides methods of treating diseases and/or conditions through binding of the nuclear receptor by the compounds and the production of medicaments using the compounds.

FXR NR1H4 nuclear receptor binding compounds

The present invention relates to compounds according to the general formula (I) which bind to the nuclear receptor, NR1H4, and act as agonists and antagonists of the NR1H4 receptor. The invention further relates to the treatment of diseases and/or conditions through binding of the nuclear receptor by the compounds.

NR1H4 nuclear receptor binding compounds

The present invention relates to compounds according to the general formula (I) which bind to the NR1H4 receptor and act as agonists of the NR1H4 receptor. The invention further relates to the treatment of diseases and/or conditions through binding of the nuclear receptor by the compounds and the production of medicaments using the compounds.

Growing community of inventors

Bammental, Germany

Ulrich Deuschle